⌘K

BCTG

NASDAQ

BCTG Acquisition Corp.

SectorFinanceIndustryBusiness ServicesIPO2020

$10.30-0.05 (-0.48%)

News25/Ratings0

Latest news

25 items

1652dSEC
SEC Form S-8 filed by BCTG Acquisition Corp.
S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)
1659dSEC
SEC Form 424B3 filed by BCTG Acquisition Corp.
424B3 - Tango Therapeutics, Inc. (0001819133) (Filer)
1667dSEC
SEC Form EFFECT filed by BCTG Acquisition Corp.
EFFECT - Tango Therapeutics, Inc. (0001819133) (Filer)
1667dSEC
SEC Form 424B3 filed by BCTG Acquisition Corp.
424B3 - Tango Therapeutics, Inc. (0001819133) (Filer)
1686dSEC
SEC Form S-1 filed by BCTG Acquisition Corp.
S-1 - Tango Therapeutics, Inc. (0001819133) (Filer)
1686d13D/G
SEC Form SC 13G filed by BCTG Acquisition Corp.
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
1707dINSIDER
SEC Form 3: Boxer Capital, LLC claimed ownership of 6,973,166 units of Common Stock
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1707dINSIDER
SEC Form 3: BCTG Holdings, LLC claimed ownership of 6,988,450 units of Common Stock
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1707d13D/G
SEC Form SC 13D filed by BCTG Acquisition Corp.
SC 13D - Tango Therapeutics, Inc. (0001819133) (Subject)
1708d13D/G
SEC Form SC 13G filed by BCTG Acquisition Corp.
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
1708d13D/G
SEC Form SC 13D filed by BCTG Acquisition Corp.
SC 13D - Tango Therapeutics, Inc. (0001819133) (Subject)
1711dINSIDER
SEC Form 4 filed by Weber Barbara
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1711dINSIDER
SEC Form 4 filed by Beckman Daniella
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1711dINSIDER
SEC Form 4 filed by Huang Alan
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1714dSEC
SEC Form 8-K filed by BCTG Acquisition Corp.
8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
1715dINSIDER
SEC Form 3: Weber Barbara claimed ownership of 1,367,592 units of Common Stock
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3: Beckman Daniella claimed ownership of 63,867 units of Common Stock
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3 filed by Peters Malte
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3 filed by Rothenberg Mace
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3 filed by Borisy Alexis
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3 filed by Huber Reid M
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3: Huang Alan claimed ownership of 135,887 units of Common Stock
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3 filed by Calhoun Lesley Ann
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1715dINSIDER
SEC Form 3: Third Rock Ventures IV, L.P. claimed ownership of 19,363,975 units of Common Stock
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
1717dPR
Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies
– Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "TNGX" – – Total expected cash position of approximately $515 million including gross proceeds from transaction totaling approximately $342 million, combining funds held in BCTG's trust account and PIPE financing once completed – CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango Therapeutics" or "Tango"), a biotechnology company committed to discovering and delivering the next generation of prec